Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science

Patrick G. Groothuis, Sun-Wei Guo, Sun‐Wei Guo
Reproductive sciences (Thousand Oaks, Calif.) · 2018 · vol. 25(9) , pp. 1318–1329 · doi:10.1177/1933719118785767 · PMID:29962279 · W2810570322
article OA: closed CC0 ⤵ 9 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

This editorial explains the complexities of drug development for endometriosis and adenomyosis, aiming to educate academic scientists and attract pharmaceutical industry interest.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This editorial discusses why pharmaceutical drug-development interest and investment in therapeutics for women with endometriosis/adenomyosis appears limited, despite many druggable targets originating in academia. It highlights the complexity of bringing drugs to patients, including intellectual property considerations, scientific rigor, the need for predictive translational models, and biomarkers, while acknowledging that only industry typically has the resources to advance compounds clinically. The paper explicitly frames its discussion as aiming to inform and align the endometriosis/adenomyosis research community with industry decision drivers, rather than presenting new experimental results, which limits it as direct evidence about efficacy or targets. Relevance to endometriosis: the article is explicitly focused on drug development for endometriosis and also addresses adenomyosis, emphasizing gaps in industry pipeline interest and the translational/biomarker hurdles for these conditions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisadenomyosis

MeSH descriptors

Adenomyosis Drug Industry Endometriosis Research Adenomyosis Endometriosis Female Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (66)

Cited by (9)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:43.094626+00:00
License: CC0 · commercial use OK